|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:dateCreated |
2006-7-31
|
|
pubmed:databankReference |
|
|
pubmed:abstractText |
Even today, treatment of Stage III NSCLC still poses a serious challenge. So far, surgical resection is the treatment of choice. Patients whose tumour is not resectable or who are unfit to undergo surgery are usually referred to a combined radio-chemotherapy. However, combined radio-chemotherapeutic treatment is also associated with sometimes marked side effects but has been shown to be more efficient than radiation therapy alone. Nevertheless, there is a significant subset of patients whose overall condition does not permit administration of chemotherapy in a combined-modality treatment. It could be demonstrated though, that NSCLCs often exhibit over-expression of EGF-receptors hence providing an excellent target for the monoclonal EGFR-antagonist cetuximab (Erbitux) which has already been shown to be effective in colorectal as well as head-and-neck tumours with comparatively mild side-effects.
|
|
pubmed:commentsCorrections |
http://linkedlifedata.com/resource/pubmed/commentcorrection/16681848-10213228,
http://linkedlifedata.com/resource/pubmed/commentcorrection/16681848-10213503,
http://linkedlifedata.com/resource/pubmed/commentcorrection/16681848-10561343,
http://linkedlifedata.com/resource/pubmed/commentcorrection/16681848-10655437,
http://linkedlifedata.com/resource/pubmed/commentcorrection/16681848-10873065,
http://linkedlifedata.com/resource/pubmed/commentcorrection/16681848-11173137,
http://linkedlifedata.com/resource/pubmed/commentcorrection/16681848-11432891,
http://linkedlifedata.com/resource/pubmed/commentcorrection/16681848-11872283,
http://linkedlifedata.com/resource/pubmed/commentcorrection/16681848-11894012,
http://linkedlifedata.com/resource/pubmed/commentcorrection/16681848-12065566,
http://linkedlifedata.com/resource/pubmed/commentcorrection/16681848-12422314,
http://linkedlifedata.com/resource/pubmed/commentcorrection/16681848-15217966,
http://linkedlifedata.com/resource/pubmed/commentcorrection/16681848-15269313,
http://linkedlifedata.com/resource/pubmed/commentcorrection/16681848-16301597,
http://linkedlifedata.com/resource/pubmed/commentcorrection/16681848-16467544,
http://linkedlifedata.com/resource/pubmed/commentcorrection/16681848-6086719,
http://linkedlifedata.com/resource/pubmed/commentcorrection/16681848-8625152,
http://linkedlifedata.com/resource/pubmed/commentcorrection/16681848-9632446
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:issn |
1471-2407
|
|
pubmed:author |
pubmed-author:BischoffHH,
pubmed-author:DebusJJ,
pubmed-author:HaberkornUU,
pubmed-author:HaselmannRR,
pubmed-author:HeegerSS,
pubmed-author:HerfarthK KKK,
pubmed-author:HoessAA,
pubmed-author:HuberP EPE,
pubmed-author:JensenA DAD,
pubmed-author:KrempienRR,
pubmed-author:MünterM WMW,
pubmed-author:NillSS,
pubmed-author:SteinsMM,
pubmed-author:SterzingFF,
pubmed-author:ThomasMM,
pubmed-author:TimkoMM
|
|
pubmed:issnType |
Electronic
|
|
pubmed:volume |
6
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
122
|
|
pubmed:dateRevised |
2009-11-19
|
|
pubmed:meshHeading |
pubmed-meshheading:16681848-Adult,
pubmed-meshheading:16681848-Antibodies, Monoclonal,
pubmed-meshheading:16681848-Antineoplastic Agents,
pubmed-meshheading:16681848-Carcinoma, Non-Small-Cell Lung,
pubmed-meshheading:16681848-Combined Modality Therapy,
pubmed-meshheading:16681848-Feasibility Studies,
pubmed-meshheading:16681848-Female,
pubmed-meshheading:16681848-Humans,
pubmed-meshheading:16681848-Lung Neoplasms,
pubmed-meshheading:16681848-Male,
pubmed-meshheading:16681848-Prospective Studies,
pubmed-meshheading:16681848-Radiotherapy, Intensity-Modulated,
pubmed-meshheading:16681848-Receptor, Epidermal Growth Factor
|
|
pubmed:year |
2006
|
|
pubmed:articleTitle |
Treatment of non-small cell lung cancer with intensity-modulated radiation therapy in combination with cetuximab: the NEAR protocol (NCT00115518).
|
|
pubmed:affiliation |
Dept. of Radiation Oncology, Clinical Radiology, University of Heidelberg Medical School, INF 400, 69120 Heidelberg, Germany. a.jensen@dkfz.de
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't,
Clinical Trial, Phase II
|
